Skip to main content

Table 6 Clinical data of included studies for the efficacy of SVR on all-cause and liver-specific mortality in patients with CHC

From: Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

Study Nationality Age Duration of follow up Study format Genotype NOS Treatment Death/Total SVR Death/No SVR Histology
Yosida H et al. (2002) [47] Japan Tx: 49.5, control: 54.6 (mean) mean 5.4 years R unknown 8 IFN-α or IFN-β a7/817 a49/1613 F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVR
Okanoue T et al. (2002) [53] Japan Tx: 50.4, control: 58.1 (mean) Mean 5.6 years R unknown 7 IFN-α or lymphoblastoid 2/426 a0/426 47/994 a34/994 F3,4: 20.9% in SVR, 34.4% in control
Imazeki F et al. (2003) [48] Japan Tx: 49.2, control: 53.1 (mean) mean 8.2 years R 73.9% type 1 8 IFN-α or IFN-β 4/116 a1/116 29/239 a18/239 F3,4: 26.7% in Tx, 29.8% in control
Coverdale SA et al. (2004) [36] Australia Tx: 37, control: 38 (median) median 9 years P 39.6% type 1 7 IFN-α a1/50 a35/334 Scheuer fibrosis score 2
Kasahara A et al. (2004) [17] Japan Tx: 53, control: 54 (median) mean 6 years R unknown 8 IFN 7/738 a1/738 94/1930 a68/1930 F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVR
Shiratori Y et al. (2005) [38] Japan Tx: 57, control: 61 (median) median 6.8 years P 71.9% type 1b 8 IFN-α or lymphoblastoid 1/64 a0/64 44/207 a32/207 unknown
Yu ML et al. (2006) [39] Taiwan Tx: 46.9, control: 43.6 (mean) mean 5.18–5.15 years R 46.2% type 1 8 IFN-α with or without RBV 4/715 a3/715 12/342 a11/342 LC 15.6% in Tx, 12.1% in control
Arase Y et al. (2007) [75] Japan SVR: 63, no SVR: 64 (mean) mean 7.4 years R 60.4% type 1b 8 IFN-α/β with or without RBV 9/140 a2/140 44/360 a32/360 F3,4: 14.5 in SVR, 27.5 in no SVR
Bruno S et al. (2007) [56] Italy 54.7 (mean) Mean 96.1 months R 71.8% type 1 8 IFN-α 6/124 a2/120 114/759 a83/728 Child A LC
Veldt BJ et al. (2007) [58] Europe and Canada 48 (median) median 2.1 years R 59% type 1 8 IFN/PegIFN with or without RBV 2/142 a1/142 24/337 a19/337 Ishak 4–6
Cardoso AC et al. (2010) [63] France 55 (mean) median 3.5 years R 60% type 1 7 IFN/PegIFN with or without RBV a3/103 a18/204 F3,4: 100%
Morgan TR et al. (2010) [64] US 48.6–49.6 (mean) median 79–96 months P 87.2% type 1 8 PegIFN with or without RBV a1/140 a23/386 F3,4: 100%
Innes HA et al. (2011) [76] UK 41.8 (mean) mean 5.3 years R 35.6% type 1 8 IFN/PegIFN with or without RBV 13/560 a5/560 75/655 a50/655 85.8% no LC
Di Martino V et al. (2011) [41] France unknown median 59 months R 57.9% type 1 7 IFN with or without RBV, or PegIFN with RBV 0/59 a0/59 9/125 a5/125 55.5% F2 or greater
Velosa J et al. (2011) [65] Portugal 51.7 (mean) mean 6.4 years R 61% type 1 7 IFN/PegIFN with or without RBV a0/39 a15/91 compensated LC
Iacobellis A et al. (2011) [66] Italy 59–62 (mean) mean 51 months P 57.3% type 1 7 PegIFN with RBV a2/24 a23/51 decompensated LC
Backus LI et al. (2011) [69] US 51–53 (mean) median 3.8 years R 72.1% type 1 6 PegIFN with RBV 525/7434 1440/9430 13% LC
Yamasaki K et al. (2012) [49] Japan 60.9 (mean) median 11.5 years P 59.9% type 1b 7 IFN-α or β or lymphoblastoid with or without RBV 9/72 a1/72 16/80 a5/80 unknown
van der Meer AJ et al. (2012) [71] Europe and Canada 48 (mean) median 8.4 years R 68% type 1 8 IFN/PegIFN with or without RBV 13/125 a3/125 100/405 a103/405 Ishak 4–6
Maruoka D et al. (2012) [43] Japan 50.4–54 (mean) mean 9.9 years R 73.6% type 1 8 IFN-α/IFN-β with or without RBV 10/221 a2/221 74/356 a50/356 F3,4: 24.3% in Tx, F4: 43.1% in control
Cozen ML et al. (2013) [44] US 50.98 (mean) mean 10 years R 68.7% type 1 8 IFN-α with or without RBV 6/69 25/90 F3,4: 19% (30.2% in Tx, 10.1% in control)
Alfaleh FZ et al. (2013) [72] Saudi Arabia, Egypt 48 (mean) mean 63.8 months P 30.6% type 4 8 PegIFN with or without RBV 0/62 a0/62 4/95 a8/95 F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR)
Aleman S et al. (2013) [45] Sweden 51 (mean) mean 5.3 years R 50% type 1 8 PegIFN with RBV 11/110 a4/110 48/193 a35/193 LC
Singal AG et al. (2013) [77] US 48 (median) median 36–72 months R 68.6% type 1 7 PegIFN with RBV 2/83 41/159 17.3% LC
Dieperink E et al. (2014) [78] US 51.4 (mean) median 7.5 years R 70% type 1 8 IFN/PegIFN with or without RBV 19/222 a6/222 81/314 a56/314 F3,4: 54.5% (41.3% in SVR, 64.7% in no SVR)
Kutala BK et al. (2015) [50] France 50 (median) median 5.5 years R 55.7% type 1 8 IFN/PegIFN with or without RBV 3/104 27/221 F3,4: 100%
Di Marco V et al. (2016) [73] Italy 58 (mean) median 7.6 years P 83.4% type 1 8 PegIFN with RBV a8/108 a98/336 compensated LC
  1. a: Liver-specific death, SVR sustained virologic response, CHC chronic hepatitis C, NOS Newcastle-Ottawa scale, Tx treatment group, R retrospective cohort study, P prospective cohort study, RCT randomized controlled study, IFN interferon, PegIFN pegylated interferon, RBV ribavirin, LC liver cirrhosis